Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Operating Leases (2019 - 2025)

Ocular Therapeutix has reported Operating Leases over the past 7 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Operating Leases at $2.8 million for Q4 2025, down 47.33% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (down 47.33% YoY), and the annual figure for FY2025 was $2.8 million, down 47.33%.
  • Operating Leases for Q4 2025 was $2.8 million at Ocular Therapeutix, down from $3.6 million in the prior quarter.
  • Over the last five years, Operating Leases for OCUL hit a ceiling of $8.7 million in Q4 2022 and a floor of $2.8 million in Q4 2025.
  • Median Operating Leases over the past 5 years was $6.0 million (2021), compared with a mean of $6.0 million.
  • Biggest five-year swings in Operating Leases: skyrocketed 57.29% in 2023 and later crashed 47.33% in 2025.
  • Ocular Therapeutix's Operating Leases stood at $5.9 million in 2021, then surged by 46.49% to $8.7 million in 2022, then decreased by 20.74% to $6.9 million in 2023, then dropped by 22.29% to $5.3 million in 2024, then crashed by 47.33% to $2.8 million in 2025.
  • The last three reported values for Operating Leases were $2.8 million (Q4 2025), $3.6 million (Q3 2025), and $4.4 million (Q2 2025) per Business Quant data.